Paradigm will use the proceeds to refinance its existing credit facility and primarily expand its domestic commercial operations for its coflex Interlaminar stabilization device for patients with spinal stenosis. The device was approved by the FDA in 2012 and is sold in more than 50 countries.
More Articles on Devices:
Is Biomet Next to Form IPO?
Bioventus Names VP of Global Marketing
Aurora Spine Appoints New VP of Sales
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
